Literature DB >> 9816106

Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme.

A C Scheck1, J R Shapiro, S W Coons, S A Norman, P C Johnson.   

Abstract

We and others have reported that human malignant gliomas demonstrate intratumor heterogeneity in which many regions may be benign; however, the presence of regions of increased malignancy in these same tumors is generally indicative of poor patient prognosis. These data suggested that tumor progression may be a local phenomenon, resulting in regions that progress to a more malignant type prior to the progression of the entire tumor. Implicit in this premise is the idea that molecular markers of tumor progression may be detectable prior to histological evidence of progression. This report details analyses performed on a primary and recurrent tumor obtained from the same patient in which the primary tumor was of a higher histological grade than the recurrent tumor. Results of molecular, cytogenetic, flow cytometric, and histological analyses of the primary tumor were indicative of a grade 4 glioblastoma multiforme. Standard cytogenetic and flow cytometric analyses demonstrated that the cells were near-diploid with a stem line population of 46,XX normal G-banded karyotypes. In contrast, tissue resected from the recurrent tumor 5 months later was histologically less malignant; however, the molecular, cytogenetic, and flow cytometric analyses of this sample demonstrated the presence of specific genetic abnormalities typically found in more malignant tumors. These data demonstrate that specific molecular and/or genetic changes leading to tumor progression may become detectable in a glioma prior to the appearance of histological features of a higher grade tumor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816106

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.

Authors:  Wolfgang K Pfisterer; Nicole C Hank; Mark C Preul; William P Hendricks; Jeanette Pueschel; Stephen W Coons; Adrienne C Scheck
Journal:  Neuro Oncol       Date:  2004-10       Impact factor: 12.300

Review 2.  Fluorescence-guided surgery for brain tumors.

Authors:  Martin Hefti
Journal:  CNS Oncol       Date:  2013-01

Review 3.  Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.

Authors:  Christine E Eyler; Jeremy N Rich
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

Review 4.  Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations.

Authors:  Kevin J Basile; Andrew E Aplin
Journal:  Adv Pharmacol       Date:  2012

5.  Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.

Authors:  Edwin Bremer; Douwe Samplonius; Bart-Jan Kroesen; Linda van Genne; Lou de Leij; Wijnand Helfrich
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

6.  Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.

Authors:  Adrienne C Scheck; Krya Perry; Nicole C Hank; W Dennis Clark
Journal:  BMC Complement Altern Med       Date:  2006-08-16       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.